Hemopexin Metabolism in Sickle-Cell Disease, Porphyrias and Control Subjects — Effects of Heme Injection

Abstract
To study hemopexin metabolism the turnover of 125I-labeled plasma hemopexin was determined in 10 control subjects, five patients with erythropoietic protoporphyria, one with porphyria cutanea tarda, and two with sickle-cell disease. Hemopexin half-life in the control subjects (mean ± S.D.) was 7.1 ± 1.0 days, and fractional catabolic rates were 23.6 ± 3.0 per cent of the plasma pool per day.